Work

Antimyeloma Activity of the Orally Bioavailable Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235

Year: 2009

Type: article

Source: Cancer Research

DOI: 10.1158/0008-5472.can-08-4285

Authors: Douglas W. McMillin, Melissa Ooi, Jake Delmore, Joseph Negri, Patrick Hayden, Nicolas Mitsiades, Jana Jakubikova, Sauveur-Michel Maira, Carlos Garcia-Echeverria, Robert Schlossman, Nikhil C. Munshi, Paul G. Richardson, Kenneth C. Anderson, Constantine S. Mitsiades

Institutions: Harvard University, Dana-Farber Cancer Institute, Novartis Institutes for BioMedical Research

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: National Institutes of Health, U.S. Public Health Service, National Cancer Institute

Awards: G1216594406, Molecular Sequelae of Myeloma-Bone Marrow Interactions: Therapeutic Applications, G800922982

OpenAlex ID: W2013036515

FWCI: 12.91

Cites: 33

Cited by: 124

Related to: 10